表皮生长因子受体 V834L 和 L858R 基因突变与非小细胞肺癌患者对奥希替尼的反应有关

IF 5.3 2区 医学 Q1 ONCOLOGY JCO precision oncology Pub Date : 2024-07-01 DOI:10.1200/PO.23.00215
Nicholas P Giustini, Colin C Pritchard, Nikhil V Kamat, Manoj P Menon
{"title":"表皮生长因子受体 V834L 和 L858R 基因突变与非小细胞肺癌患者对奥希替尼的反应有关","authors":"Nicholas P Giustini, Colin C Pritchard, Nikhil V Kamat, Manoj P Menon","doi":"10.1200/PO.23.00215","DOIUrl":null,"url":null,"abstract":"<p><p>Up-front osimertinib leads to clinical benefit in EGFR V834L and L858R comutated NSCLC.</p>","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":"8 ","pages":"e2300215"},"PeriodicalIF":5.3000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"<i>EGFR</i> V834L and L858R Comutation Is Associated With Response to Osimertinib in Non-Small-Cell Lung Cancer.\",\"authors\":\"Nicholas P Giustini, Colin C Pritchard, Nikhil V Kamat, Manoj P Menon\",\"doi\":\"10.1200/PO.23.00215\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Up-front osimertinib leads to clinical benefit in EGFR V834L and L858R comutated NSCLC.</p>\",\"PeriodicalId\":14797,\"journal\":{\"name\":\"JCO precision oncology\",\"volume\":\"8 \",\"pages\":\"e2300215\"},\"PeriodicalIF\":5.3000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JCO precision oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1200/PO.23.00215\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCO precision oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1200/PO.23.00215","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

奥希替尼可使表皮生长因子受体 V834L 和 L858R 组合型 NSCLC 患者获得临床获益。
本文章由计算机程序翻译，如有差异，请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
EGFR V834L and L858R Comutation Is Associated With Response to Osimertinib in Non-Small-Cell Lung Cancer.

Up-front osimertinib leads to clinical benefit in EGFR V834L and L858R comutated NSCLC.

求助全文
通过发布文献求助，成功后即可免费获取论文全文。 去求助
来源期刊
JCO precision oncology
JCO precision oncology ONCOLOGY-
CiteScore
9.10
自引率
4.30%
发文量
363
期刊最新文献
DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial. Erratum: Tumor Characteristics Associated With Preoperatively Detectable Tumor-Informed Circulating Tumor DNA in Patients With Renal Masses Suspicious for Renal Cell Carcinoma. DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance. KRASG12D-Mutated Metastatic Colorectal Cancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted Alteration. Neo-wt-RAS in ctDNA: Is It Worth Using Anti-EGFR Therapies?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1